Abstract
Atopic dermatitis (AD) is a chronic pruritic inflammatory dermatosis. Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyse the hydrolysis of cyclic AMP (cAMP), a second messenger that controls key cellular functions, into its inactive forms. Selective inhibitors of PDE4, a cAMP-specific PDE, serve as potent anti-inflammatory agents. To measure PDE4 gene expression in patients with AD before and after treatment with topical mometasone cream, in comparison to controls Twenty patients with acute and subacute AD were investigated. Skin biopsies before and after treatment were obtained for evaluation of PDE4 expression level by RT-PCR The level of PDE4 mRNA was significantly higher in AD patients either before or after treatment compared to controls (p < 0.001), and the level of PDE4 mRNA in AD patients significantly decreased following treatment (p < 0.001) Our study indicates that there is an increased level of PDE4 in AD lesions, suggesting that PDE4 plays an important role in the pathogenesis of AD. Targeting PDE4 (using PDE4 inhibitors) may herald a new era in the treatment of AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
